PepGen (PEPG) Net Income towards Common Stockholders (2021 - 2026)
PepGen (PEPG) posted Net Income towards Common Stockholders of -$17.8 million for Q1 2026, up 2.89% sequentially from -$18.3 million in Q4 2025, and up 41.19% YoY from -$12.6 million in Q1 2025.
Powered by 
Analysis
PepGen (PEPG) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
PepGen has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$17.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 41.19% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.2 million (up 24.92% YoY) and the FY2025 annual result came in at -$89.7 million, changed 0.36% from the prior year.
- Net Income towards Common Stockholders improved to -$17.8 million in Q1 2026 per PEPG's latest filing, from -$18.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$16.3 million in Q1 2023 and troughed at -$46.3 million in Q4 2022.
- A 5-year average of -$22.2 million and a median of -$19.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders plunged 4709.24% in 2022, then jumped 58.06% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at -$46.3 million in 2022, then surged by 58.06% to -$19.4 million in 2023, then decreased by 17.7% to -$22.9 million in 2024, then grew by 19.98% to -$18.3 million in 2025, then gained by 2.89% to -$17.8 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$17.8 million, -$18.3 million, and -$18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | -17.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.81 Mn |
| Mar 31, 2026 | -17.76 Mn |
| Dec 31, 2025 | -18.29 Mn |
| Sep 30, 2025 | -18.03 Mn |
| Jun 30, 2025 | -23.09 Mn |
| Mar 31, 2025 | -30.20 Mn |
| Dec 31, 2024 | -22.86 Mn |
| Sep 30, 2024 | -21.38 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Mar 31, 2024 | -18.02 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Sep 30, 2023 | -23.29 Mn |
| Jun 30, 2023 | -19.52 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -46.31 Mn |
| Sep 30, 2022 | -18.61 Mn |
| Jun 30, 2022 | -17.32 Mn |
| Mar 31, 2022 | -18.25 Mn |
| Dec 31, 2021 | -7.14 Mn |
| Sep 30, 2021 | -8.11 Mn |